BioAdvance News

Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19

By WebmasterJuly 28, 2020November 1st, 2024No Comments

Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19
Up to $13.3M funding to accelerate development and early clinical testing of antibodies derived from large-scale B cell interrogation of COVID-19 “Super-Responders”

See more here

Previous PostInfraScan Inc. Announces Issuance of US Patents for Brain Diagnosis
Next PostVenatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostInfraScan Inc. Announces Issuance of US Patents for Brain Diagnosis

Next PostVenatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen